Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2509-2520

  Bergen, Phillip J ^a   Bulitta, Jürgen B ^b   Kirkpatrick, Carl M J ^a   Rogers, Kate E ^a   McGregor, Megan J ^a   Wallis, Steven C ^c   Paterson, David L ^d   Lipman, Jeffrey ^c,e   Roberts, Jason A ^c,e   Landersdorfer, Cornelia B ^a,f  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PIPERACILLIN;

CRITICAL ILLNESS; DRUG EFFECTS; HUMAN; KIDNEY; MICROBIAL SENSITIVITY TEST; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; KIDNEY; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84994725046     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw153     Document Type: Article

References (46)

1. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
2. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
3. Roberts JA, Paul SK, Akova M et al. DALI: defining antibiotic levels in intensive care unit patients: are current b-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58: 1072-83.
4. Tabah A, DeWaele J, Lipman J et al. The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 2015; 70: 2671-7.
5. Valenza G, Seifert H, Decker-Burgard S et al. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany. Int J Antimicrob Agents 2012; 39: 255-8.
6. Eagye KJ, Banevicius MA, Nicolau DP. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Crit Care Med 2012; 40: 1329-32.
7. Adnan S, Li JX, Wallis SC et al. Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. Int J Antimicrob Agents 2013; 42: 90-3.
8. Roberts JA, Kirkpatrick CM, Roberts MS et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35: 156-63.
9. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6: 234-44.
10. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67: 351-68.
11. Udy AA, Lipman J, Jarrett P et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 2015; 19: 28.
12. Roberts JA, Kruger P, Paterson DL et al. Antibiotic resistance-what's dosing got to do with it? Crit Care Med 2008; 36: 2433-40.
13. Felton TW, Goodwin J, O'Connor L et al. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013; 57: 5811-9.
14. Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 1985; 15 Suppl A: 131-7.
15. Velkov T, Bergen PJ, Lora-Tamayo J et al. PK/PD models in antibacterial development. Curr Opin Microbiol 2013; 16: 573-9.
16. Udy AA, Putt MT, Boots RJ et al. ARC-augmented renal clearance. Curr Pharm Biotechnol 2011; 12: 2020-9.
17. Hobbs AL, Shea KM, Roberts KM et al. Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics. Pharmacotherapy 2015; 35: 1063-75.
18. Schortgen F, Asfar P. Update in sepsis and acute kidney injury 2014.Am J Respir Crit Care Med 2015; 191: 1226-31.
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
20. EUCAST. Breakpoint Tables for Interpretation ofMICs and Zone Diameters, Version 6.0, 1 January 2016. http://www.eucast.org/clinical-breakpoints/.
21. Cadwell JJS. The hollow fibre infection model for antimicrobial pharmacodynamics and pharmacokinetics. Adv Pharmacoepidem Drug Safety 2012; doi:10.4172/2167-1052.S1-007.
22. Louie A, CastanheiraM, LiuWet al. Pharmacodynamics of b-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of b-lactamases. Antimicrob Agents Chemother 2012; 56: 258-70.
23. Roberts JA, Ulldemolins M, Roberts MS et al. Therapeutic drug monitoring of b-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36: 332-9.
24. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical Method Validation. Rockville, MD, USA, 2001. www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
25. EMA. Guideline on Bioanalytical Method Validation. London, UK, 2011. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf.
26. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.
27. Bulitta JB, Landersdorfer CB. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 2011; 13: 212-26.
28. Bulitta JB, Bingolbali A, Shin BS et al. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 2011; 13: 201-11.
29. Jitmuang A, Nation RL, Koomanachai P et al. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. J Antimicrob Chemother 2015; 70: 1804-11.
30. Landersdorfer CB, Ly NS, Xu H et al. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 2013; 57: 2343-51.
31. Bulitta JB, Ly NS, Yang JC et al. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 46-56.
32. Drusano GL, Liu W, Fikes S et al. Interaction of drug- and granulocytemediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis 2014; 210: 1319-24.
33. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-12.
34. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-6.
35. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
36. Li C, Du X, Kuti JL et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
37. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
38. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41: 489-95.
39. Udy AA, Varghese JM, Altukroni M et al. Subtherapeutic initial b-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-9.
40. VanScoy BD, Mendes RE, Castanheira M et al. Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother 2014; 58: 6024-31.
41. Yadav R, Landersdorfer CB, Nation RL et al. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2015; 59: 2286-98.
42. Tsuji BT, Okusanya OO, Bulitta JB et al. Application of pharmacokineticpharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis 2011; 52 Suppl 7: S513-9.
43. Louie A, Liu W, VanGuilder M et al. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. J Infect Dis 2015; 211: 1326-33.
44. Drusano GL, Bonomo RA, Bahniuk N et al. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012; 56: 231-42.
45. Louie A, Bied A, Fregeau C et al. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 2010; 54: 2638-45.
46. Tam VH, Louie A, Deziel MR et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192: 420-8.